National Ambulatory Care Reporting System (NACRS) (Canada) **

Database Contact Data

Email: help@cihi.ca
Phone: +1 613-241-5543

Alternate Contact

1. CIHI publishes a wealth of publicly available statistics (see https://www.cihi.ca/en/access-data-and-reports).

2. If you’re looking for more detailed information, you can make a custom data request by using their Data Inquiry Form at https://www.cihi.ca/en/data-inquiry-form.

References of Studies Using/Describing Database

1. Burgesson B, Lethbridge L, Haase D, Dunbar M; Published in collaboration with the Health Association of African Canadians. Disparities in Utilization Rates of Total Knee and Hip Arthroplasty Among Racially Visible Populations in Canada: A Retrospective Cohort Analysis. J Arthroplasty. 2025 Apr 11:S0883-5403(25)00336-5.

2. Dick K, Kaczmarek E, Ducharme R, Bowie AC, Dingwall-Harvey ALJ, Howley H, Hawken S, Walker MC, Armour CM. Transformer-based deep learning ensemble framework predicts autism spectrum disorder using health administrative and birth registry data. Sci Rep. 2025 Apr 7;15(1):11816.

3. Yin CY, Scott MM, Talarico R, Hakimjavadi R, Kierulf J, Webber C, Hawken S, Moledina A, Manuel D, Hsu A, Tanuseputro P, Fung C, Kaasalainen S, Molnar F, Shamon S, McIsaac DI, Kobewka D. Transfer from long-term care to acute care and risk of new permanent cognitive or physical disability among long-term care residents in Canada: protocol for a retrospective cohort study. BMJ Open. 2025 Jan 20;15(1):e086932.

4. Yao X, Champagne AS, McFaull SR, Thompson W. Temporal trends and characteristics of fall-related deaths, hospitalizations and emergency department visits among older adults in Canada. Health Promot Chronic Dis Prev Can. 2024 Nov;44(11-12):482-487.

5. Mirzadeh P, Kuk JL, Wharton S, Reid RA, Ardern CI. Healthcare outcomes and dispositions in persons with obesity within emergency departments in Ontario, Canada: A cross-sectional analysis of the National Ambulatory Care Reporting System (NACRS), 2018-2022. PLoS One. 2024 Sep 26;19(9):e0311190.

6. Khalid A, Muchaal PK, Julien DA. Human echinococcosis incidence in Canada: A retrospective descriptive study using administrative hospital and ambulatory visit data, 2000-2020. Can Commun Dis Rep. 2024 Sep 5;50(9):305-311.

7. Dengler J, Perlman M, Jennett M, Marcon E, Guilcher S. An Examination of Utilization Rates Over Time of Nerve and Tendon Transfers in Canada to Improve Upper Limb Function in Cervical Spinal Cord Injury. Plast Surg (Oakv). 2024 Aug;32(3):367-373.

8. Brissette V, Kapral MK, Yu B, Fang J, Odugbemi T, Shamy M, Fahed R, Dowlatshahi D, Gocan S, Martineau I. Seasonal Variations in Stroke Occurrence. Neuroepidemiology. 2024 Jul 22:1-10.

9. Ferro MA, Chan CKY, Browne DT, Colman I, Dubin JA, Duncan L. Suicidal Ideation and Attempts Among Youth With Physical-Mental Comorbidity in Canada: Proposal for an Epidemiological Study. JMIR Res Protoc. 2024 Jul 4;13:e57103.

10. Benny C, Hobin E, Andreacchi AT, Schwartz N, Smith BT. Socio-economic inequities in emergency department visits for wholly alcohol-attributable acute and chronic harms in Canada, 2003-2017. Drug Alcohol Rev. 2024 May;43(4):927-936.

Mar 30, 2023: Introducing BADBIR, a UK psoriasis registry

The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a national register of all patients receiving biologic therapy for the treatment of psoriasis in the United Kingdom. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for Psoriasis should be registered in BADBIR. BADBIR has grown to be the largest psoriasis study of its kind globally.

British Association of Dermatologists Biologic Interventions Register (BADBIR) (United Kingdom) **

Database Contact Data

BADBIR
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Main Office Phone: +44 0161 306 1896
Email: badbir@manchester.ac.uk

Alternate Contact

1. Ian Evans
Manager
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Email: Ian.Evans@manchester.ac.uk

2. If you are interested in using BADBIR data as a researcher, please email Zin Mon (Research Manager) at research@bad.org.uk to describe your data request.

References of Studies Using/Describing Database

1. Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou A, Davies E, Smith CH, Griffiths CEM, Morris AP, Warren RB; BSTOP Study Group and the BADBIR Study Group. Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics. J Invest Dermatol. 2023 Aug;143(8):1470-1478.e1.

2. Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Br J Dermatol. 2023 Jul 7;189(1):62-70.

3. Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023 May 25:ljad179. doi: 10.1093/bjd/ljad179. Epub ahead of print.

4. Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol. 2023 Apr 20;188(5):618-627. 

5. Tillett W, Ogdie A, Passey A, Gorecki P. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. RMD Open. 2023 Jan;9(1):e002533. 

6. Yiu ZZ, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CE, Browne F, Evans I, Kleyn E. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA dermatology. 2022 Oct 1;158(10):1131-41.

7. Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis. J Invest Dermatol. 2022 Jun;142(6):1617-1628.e10.

8. Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J. Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific reports. 2021 Dec 2;11(1):1-4.

9. Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN, Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium. Defining trajectories of response in patients with psoriasis treated with biologic therapies. Br J Dermatol. 2021 Oct;185(4):825-835.

10. Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD; BADBIR Study Group. Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e496-e498.

Mar 22, 2023: Why are some databases not currently profiled on B.R.I.D.G.E. TO DATA®?

The main goal of B.R.I.D.G.E. is to profile databases from around the world with the most current information. Therefore, B.R.I.D.G.E. profiles databases as new ones are created. We usually work with each database manager to ensure their database profile is complete and accurate. Although we try to include as many profiles on our web site as possible, we unfortunately cannot profile every database.

Mar 14, 2023: Read about our 8th healthcare database profile from Estonia

Established in January 2015, the Estonian Cancer Screening Register records data on the 3 available population-based cancer screenings in Estonia: breast, cervical and colorectal cancer. While the breast cancer screening started in 2003, and the cervical cancer screening in 2006, the data have been added to ECSR only since 2015, while colorectal cancer screening data in Estonia were added to the register in 2016.

National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) (United Kingdom)

Database Contact Data

For requests for data which sit under the National Congenital Anomaly and Rare Diseases Registration Service (NCARDRS) suite of products, please email ndrsenquiries@nhs.net.

To discuss any aspect of DARS or an existing application call the team on +44 (0)300 303 5678 or email enquiries@nhsdigital.nhs.uk.

Alternate Contact

1. Danielle Martin
National Senior Data Analyst 
National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) 
Public Health England
Wellington House
133-155 Waterloo Road
London, England SE1 8UG
UNITED KINGDOM
Email: danielle.martin@phe.gov.uk  
Phone: +44 (0)191 242 6003
Mobile: +44 (0) 7554111236

2. If you cannot reach the database manager, you may contact the organization by completing the contact form at: https://digital.nhs.uk/ndrs/ndrs-contact-page

References of Studies Using/Describing Database

1. Cave DGW, Wands ZE, Cromie K, Hough A, Johnson K, Mon-Williams M, Bentham JR, Feltbower RG, Glaser AW. Educational attainment of children with congenital heart disease in the United Kingdom. Eur Heart J Qual Care Clin Outcomes. 2024 Aug 8;10(5):456-466. 

2. Broughan JM, Martin D, Higgins T, Swan G, Cullum A, Kurinczuk JJ, Draper ES, Luyt K, Wellesley DG, Stevens S, Tedstone A, Rankin J. Prevalence of neural tube defects in England prior to the mandatory fortification of non-wholemeal wheat flour with folic acid: a population-based cohort study. Arch Dis Child. 2024 Jan 22;109(2):106-112.

3. Broughan JM, Wreyford B, Martin D, Melis G, Randall K, Obaro E, Broggio J, Aldridge N, Stoianova S, Johnson C, Gibbard D, Stevens S, Fleming KM. Cohort profile: the National Congenital Anomaly Registration Dataset in England. BMJ Open. 2024 Jan 12;14(1):e077743.

4. Odingo M, Rutter M, Bowley J, Peach EJ, Lanyon PC, Grainge MJ, Stillwell P, McPhail S, Bythell M, Aston J, Stevens S, McCormack R, Brogan P, Pearce FA. The incidence of Kawasaki disease using hospital admissions data for England 2006-2021. Rheumatology (Oxford). 2023 Sep 1;62(9):3117-3125.

5. Moss C, Roked F, Davis PJ, Khan M, Tyler C, Ibbs S, Ewer AK. Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study. British Journal of Dermatology. 2023 Jan;188(1):139-40.

6. Aldridge N, Pandya P, Rankin J, Miller N, Broughan J, Permalloo N, McHugh A, Stevens S. Detection rates of a national fetal anomaly screening programme: A national cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2023 Jan;130(1):51-8.

7. Melis G, Martin D, Obaro E, Tempest E, Broughan J, Miller N. P25 The national congenital anomaly and rare disease registration service (NCARDRS): data profile, its application and development towards administrative data linkage in England. 2023; A65-A66.

8. Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF, Go-DS21 Consortium, Herault Yann Strydom Andre Chan Li Potier Marie-Claude Beckers Johannes Liò Pietro Dierssen Mara. Diabetes and obesity in Down Syndrome across the lifespan: a retrospective cohort study using UK electronic health records. Diabetes care. 2022 Dec;45(12):2892-9.

9. West J, Stilwell P, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Bishton M, Crooks C. Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England. Blood. 2022 Nov 15;140(Supplement 1):5469-70.

10. Bishton M, Crooks C, Liu H, Ban L, Bythell M, Card T, Lanyon P, Nanduri V, Rankin J, Stilwell P, West J. Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors. Blood. 2022 Nov 15;140(Supplement 1):2599-600.

Subscribe to